#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO\	/AL
OMB Number:	3235-0287
Estimated average but	rden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * SHERWIN STEPHEN A				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/13/2015						_Officer (giv	e title below)	Oth	r (specify below)	
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)					_X_	6. Individual or Joint/Group Filing(Check Applicable Line)  _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
		NCISCO, CA 94 (State)												
(Cit	y)	(State)	(Zip)			Table 1	I - Non-Deri	vative Securitie	s Acquired	l, Disposed	of, or Bene	ficially Own	ed	
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	Executi any			(	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		d	Ownership of Indi	eneficial	
			(Month	/Day/Year	Coo	de V A	(A) or (D)	(Ins	(Instr. 3 and 4)		0	Direct (D) Or Indirect (I) Instr. 4)	Ownership Instr. 4)	
Reminder:	report on a s	-						s who respon form are not r					ned SEC 14	174 (9-02)
	•		Table II -	(e.g., pu			in this display uired, Disp		equired to valid OME eficially Ow ities)	respond 3 control r	unless the number.	e form		174 (9-02)
1. Title of	2. Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	ts, calls, w 5. Nu of De Secur Acqu	mber rivative ities ired (A) sposed	in this display uired, Display options, co	form are not rest a currently osed of, or Bene onvertible securercisable and Date	equired to valid OME eficially Ow ities)	o respond 3 control r wned d Amount ying	unless the number.		f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nation of Indirection Benefic Owners (Instr. 4
Title of     Derivative     Security	2. Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	5. Nution of De Securior Di of (D	mber rivative ities red (A) posed	in this display quired, Disp options, co do Date Exe Expiration (Month/Date Exercisable Exercisable	form are not rest a currently cosed of, or Benconvertible securercisable and Date y/Year)	equired to valid OME eficially Ow ities)  7. Title an of Underly Securities	o respond 3 control r wned d Amount ying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	f 10. Ownership Form of Derivative Security: Direct (D) or Indirect	11. Nat of Indir Benefic Owners (Instr. 4

## Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
SHERWIN STEPHEN A C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X				

## **Signatures**

/s/ Dolly Vance (Attorney-In-Fact)	05/14/2015
Signature of Reporting Person	Date

# **Explanation of Responses:**

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly over twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.